Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Cash flows from operating activities:
Net income including noncontrolling interests in operating subsidiaries	$ (58,842)	$ 59,289	$ 21,645
Adjustments to reconcile net income (loss) including noncontrolling interests in operating subsidiaries to net cash provided by (used in) operating activities:
Depreciation and amortization	53,894	39,168	9,850
Non-cash stock compensation	27,894	25,657	13,579
Excess tax benefits from stock-based compensation	1,398	(13,210)	(583)
Change in valuation allowance	2,189	(10,651)	0
Other	12	777	(15)
Changes in assets and liabilities:
Accounts receivable	3,502	(6,928)	5,072
Prepaid expenses and other assets	(5,300)	(1,294)	1,075
Accounts payable and accrued expenses / costs	1,076	16,249	(781)
Royalties and contingent legal fees payable	(2,061)	(11,000)	10,748
Deferred income tax	(27,271)	6,546	0
Net cash provided by (used in) operating activities	(3,509)	104,603	60,590
Cash flows from investing activities:
Purchase of property and equipment	(675)	(268)	(190)
Purchase of available-for-sale investments	(279,693)	(402,500)	(8,427)
Sale of available-for-sale investments	239,370	322,236	60
Purchase of ADAPTIX, Inc., net of cash acquired	0	(150,000)	0
Patent acquisition costs	(25,061)	(178,260)	(14,680)
Net cash used in investing activities	(66,059)	(408,792)	(23,237)
Cash flows from financing activities:
Proceeds from sale of common stock, net of issuance costs	0	218,961	175,229
Repurchases of common stock	(7,926)	(26,732)	0
Dividends paid to shareholders	(18,633)	0	0
Distributions to noncontrolling interests in operating subsidiary	0	(312)	(2,897)
Contributions from noncontrolling interests in operating subsidiary, net of issuance costs	1,920	5,793	1,539
Proceeds from the exercise of stock options	486	340	411
Excess tax benefits from stock-based compensation	(1,398)	13,210	583
Net cash provided by (used in) financing activities	(25,551)	211,260	174,865
Increase in cash and cash equivalents	(95,119)	(92,929)	212,218
Cash and cash equivalents, beginning	221,804	314,733	102,515
Cash and cash equivalents, ending	126,685	221,804	314,733
Patent acquisition costs included in accrued expenses	$ 4,000	$ 0	$ 900